Erschienen in:
01.01.2014 | letter to the editor
Gastrointestinal bleeding associated with dabigatran in a patient with panhypopituitarism
verfasst von:
Fahri Gunes, MD, Mehmet Asik, MD, Ahmet Temiz, MD, Emine Binnetoglu, Hacer Sen, Ogun İrem Bilen, Erdem Akbal, MD, Gurhan Adam, Kubilay Ukinc
Erschienen in:
Wiener klinische Wochenschrift
|
Ausgabe 1-2/2014
Einloggen, um Zugang zu erhalten
Excerpt
Dabigatran is a direct thrombin inhibitor that is used to reduce the risk of systemic embolism in patients with atrial fibrillation (AF). It does not require international normalised ratio (INR) monitoring during the course of treatment, and this arise from the most important advantage of this drug when compared with coumadin. The main complication of dagibatran is bleeding of the gastrointestinal system [
1]. Bleeding diathesis, renal dysfunction, age, and concomitant antiplatelet medications are associated with bleeding complications [
2]. …